Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Publication year range
1.
Cureus ; 16(5): e60281, 2024 May.
Article in English | MEDLINE | ID: mdl-38872647

ABSTRACT

Beta-lactam antibiotics are essential components in the current antimicrobial treatment strategy, playing a crucial role in ambulatory patients and hospitalized patients. Despite their prominent therapeutic index, the use of beta-lactam can lead to adverse effects, with allergic reactions being the most concerning because of their severity. Additionally, the phenomenon of cross-reactivity may occur among various beta-lactam families, with side chains significantly contributing to immunological recognition, making these structures often responsible for the cross-allergic reactivity of beta-lactams. Tools to assess beta-lactam allergy include taking a patient's medical history, performing skin tests, and conducting provocation tests. This research aims to analyze the relevant aspects related to the safe administration of beta-lactam antibiotics in hospitalized patients as well as provide knowledge on the proper management of patients with such hypersensitivity, by doing systemic research. This research was made using Google Scholar and keywords such as "Beta-lactam allergy," "Hypersensitivity," "Cross-reactivity," "Desensitization," and "Beta-lactam allergy management." In conclusion, substituting a beta-lactam antibiotic with an alternative antibiotic may not always be the best management option for these patients, as it may lead to more adverse effects, be less effective, and prolong hospitalization time. It may also result in higher rates of antibiotic-resistant infections and increased medical costs, as these alternatives are often more expensive. However, an alternative within the beta-lactam family can be sought by conducting the appropriate analyses. Although cross-reactivity does not always occur among all beta-lactams, potential cross-reactivity should always be considered.

2.
Rev. costarric. cardiol ; 25(2): 45-50, jul.-dic. 2023. tab
Article in Spanish | LILACS, SaludCR | ID: biblio-1559766

ABSTRACT

RESUMEN Introducción y objetivos : La insuficiencia cardíaca (IC) es una preocupación creciente de salud pública. Si bien los betabloqueantes (BB) son la base del tratamiento, lograr reducciones objetivo de frecuencia cardíaca puede ser difícil debido a los efectos secundarios y la tolerancia limitada. La ivabradina, un inhibidor único de la corriente If, ofrece un enfoque complementario para controlar la frecuencia cardíaca sin afectar la contractilidad. El objetivo de este estudio fue evaluar la eficacia de agregar ivabradina a la terapia BB en pacientes con IC. Métodos: Se realizó un estudio observacional retrospectivo en un hospital privado en San José, Costa Rica se analizaron 7 casos de pacientes tratados con BB a los cuales posteriormente se les adicionó ivabradina. Se recopilaron datos demo- gráficos, las características clínicas, la frecuencia cardíaca previa y posterior a la ivabradina, la clase funcional NYHA y los valores de laboratorio seleccionados. Resultados: La ivabradina redujo significativamente la frecuencia cardíaca en reposo en un promedio de 26,87 latidos por minuto. El 42,86% alcanzó la dosis meta de su BB inicial después de agregar ivabradina. La clase funcional NYHA se mantuvo estable o mejoró en todos los casos. Conclusiones: Estos resultados sugieren que agregar ivabradina a la terapia BB puede ser una estrategia eficaz para optimizar el control de la frecuencia cardíaca en pacientes con IC. Este enfoque puede mejorar la tolerabilidad de BB, lo que lleva a un mayor manejo de la dosis meta y posiblemente mejores resultados clínicos.


ABSTRACT Introduction and objectives: Heart failure (HF) is a growing public health concern. While beta-blockers (BBs) are the cornerstone of treatment, achieving target heart rate reductions can be difficult due to side effects and limited tolerance. Ivabradine, a unique inhibitor of the If current, offers a complementary approach to controlling heart rate without affecting contractility. This study aimed to evaluate the effectiveness of adding ivabradine to BB therapy in patients with HF. Methods : A retrospective observational study was conducted at a private hospital in San José, Costa Rica. Seven cases of patients treated with BBs who were subsequently added to ivabradine were analyzed. Demographic data, clinical characteristics, heart rate before and after ivabradine, NYHA functional class, and selected laboratory values were collected. Results : Ivabradine significantly reduced resting heart rate by an average of 26.87 beats per minute. Forty-two-point eight-six percent (42.86%) achieved the target dose of their initial BB after adding ivabradine. NYHA functional class remained stable or improved in all cases. Conclusions: These results suggest that adding ivabradine to BB therapy may be an effective strategy to optimize heart rate control in patients with HF. This approach may improve BB tolerability, leading to greater target dose management and possibly better clinical outcomes.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Ivabradine/therapeutic use , Heart Failure/drug therapy , Costa Rica
3.
Antibiotics (Basel) ; 12(11)2023 Oct 28.
Article in English | MEDLINE | ID: mdl-37998774

ABSTRACT

This study aims to characterize the impact of the implementation of an antimicrobial stewardship program (AMS) on the optimal selection of surgical antibiotic prophylaxis in adult patients. This is a retrospective quasi-experimental study that compared the selection and duration of antibiotics for all surgical prophylaxis prescriptions over six months, both before (pre-AMS) and after a five-year intervention of AMS (post-AMS). In addition, data related to the consumption of antibiotics, adverse drug reactions, and surgical site infections throughout the years of the intervention were analyzed. The rate of appropriate selection of antibiotic prophylaxis in surgical procedures improved to 80% during the post-AMS period. The percentage of optimal duration increased from 69.1% (N = 1598) in the pre-AMS period to 78.0% (N = 841) in the post-AMS period (p < 0.001). The consumption of ceftriaxone significantly decreased, while the use of cefazolin increased more than nine times. No severe adverse reactions or increases in surgical site infections were detected after the intervention. The implementation of an AMS in the surgical ward demonstrated a trend towards a positive overall impact on the selection and duration of prophylactic antibiotics for surgery, with positive results also observed in other variables associated with the prescription of these antibiotics.

4.
Cureus ; 15(5): e38383, 2023 May.
Article in English | MEDLINE | ID: mdl-37265915

ABSTRACT

Tetanus is a bacterial infection caused by the toxin of Clostridium tetani. While it primarily affects newborns, people with incomplete vaccination schedules, it can also impact people of any age, especially in developing countries. Even though in the last 20 years several initiatives have been implemented worldwide to reduce the impact of this disease, regions like South Asia and sub-Saharan Africa have registered mortality rates highest since 2015-2019. In Latin America, regional immunization coverage rates were reported at 89% in 2017 for diphtheria-tetanus toxoid and pertussis (DTP-3), although Costa Rica has reported decreased coverage rates of the national immunization schedule from 2019 to 2021. In this case study, we present a 53-year-old woman from Puntarenas, Costa Rica diagnosed with progressive systemic tetanus who developed status epilepticus. She previously was assessed in a central hospital of Costa Rica for paresthesia in her right upper limb of three months of duration, myoclonus and difficulty walking in the last weeks; the presumed diagnosis was Guillain-Barré syndrome. During her hospitalization she had three generalized tonic-clonic seizures treated with diazepam and phenytoin. Since there was no improvement, she was transferred to our medium-sized private hospital for the treatment of painful spasms and weakness in the lower limbs. On initial evaluation, no injury was found. She was initially treated with midazolam and magnesium sulfate for presenting seizures-like spasms in the lower limbs and then generalized without loss of consciousness for up to 15 minutes, mainly associated with desaturation, tachycardia and tachypnea. In the differential diagnosis, muscle contractions linked to hypocalcemia, neurosyphilis and epilepsy were ruled out. Despite this, magnetic resonance imaging showed fractures in T11, L1 and L2. Mainly due to the presence of spasms, opisthotonos and history of seizures and a wound on the hand four months ago, she was diagnosed with tetanus.  Among the initial management, tetanus toxoid (Td), antimicrobial therapy, and human antitetanic immunoglobulin (HTIG) were administered, which partially improved the patient's condition, although she remained dependent on the infusions. On the sixth week of hospitalization, the patient developed status epilepticus which is explained by the magnetic resonance findings that show subacute bi-occipital infarcts caused by hypoxia from the previous crises. Lacosamide therapy reversed the condition and kept the patient free of seizures.  It was necessary to carry out a lumbar osteosynthesis which was highly favorable to stabilize the patient's condition. The frequency and intensity of the spasms were gradually reduced, which allowed the gradual suspension of the infusions and the benzodiazepine overlap intravenous (IV) to oral (PO). The patient now has only self-limiting spasms and her maintenance therapy consists of lacosamide and oral clonazepam.  This case highlights the importance of considering tetanus in the differential diagnosis even if the vaccination schedule is complete, especially if there are spasms, convulsions, or a history of wounds or bites. It is important to monitor this type of report to reconsider and update the key elements in the prevention, diagnosis, management, and treatment of tetanus; as well as improve access to essential medicines, including the HTIG, and the patient's prognosis in terms of symptom resolution and associated sequelae.

SELECTION OF CITATIONS
SEARCH DETAIL
...